Post hoc analysis of 2 placebo-controlled trials in schizophrenia: aripiprazole once-monthly 400 mg gave ≥30% PANSS reduction in 37.0% vs 14.4% (NNT 5) and relapse avoidance in 90.0% vs 60.4% (NNT 4); adverse-event discontinuations were lower.
Secondary analysis
Citrome et al. Aripiprazole Once-Monthly for Patients Diagnosed With Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed